Why Is There An Increased Risk Of Severe Adverse Perinatal Outcomes After The Use Of Clomiphene Citrate For Infertility Treatment?
Funder
National Health and Medical Research Council
Funding Amount
$570,065.00
Summary
Clomiphene citrate (CC) has been a first line treatment for female infertility internationally since the 1960’s. However, safety studies using routine prescribing practices were never performed, and numerous data sources now indicate that CC is associated with major adverse outcomes if the fetus is inadvertently exposed. We are linking prescription data to perinatal outcomes to confirm how CC is associated with adverse events so as to inform prescriber and practice change.
Near Real-time Identification Of Patient Safety Incidents Reported By Health Professionals.
Funder
National Health and Medical Research Council
Funding Amount
$324,174.00
Summary
Ten percent of admissions to Australian hospitals are associated with harm to patients. Reporting of patient safety incidents is now widespread. Current methods, which rely upon humans to manually review incident reports, do not permit timely detection of safety problems and can no longer keep up with the growing volume. This study will be the first internationally to automate the monitoring of incident reports. The outcomes have broad and immediate potential to improve the monitoring of inciden ....Ten percent of admissions to Australian hospitals are associated with harm to patients. Reporting of patient safety incidents is now widespread. Current methods, which rely upon humans to manually review incident reports, do not permit timely detection of safety problems and can no longer keep up with the growing volume. This study will be the first internationally to automate the monitoring of incident reports. The outcomes have broad and immediate potential to improve the monitoring of incidents on a local, national and international scale.Read moreRead less
Q Fever: How Common Is It And How Can We Best Prevent It? Research To Inform Q Fever Vaccine Policy In Australia And Internationally
Funder
National Health and Medical Research Council
Funding Amount
$743,376.00
Summary
Q fever is a disease of worldwide importance which has special significance for Australia where outbreaks continue to occur. We will measure the burden of Q fever in the Australian population for the first time, measure how long immunity lasts following vaccination, collect extra information on adverse events in young adults and survey knowledge and attitudes of Q fever disease and vaccine. The results will inform policies for the control of Q fever in Australia and internationally.
ADding Negative PRESSure To Improve HealING (the DRESSING Trial)
Funder
National Health and Medical Research Council
Funding Amount
$2,380,446.00
Summary
The aim of this 5-year randomised comtrolled trial is to test the clinical and cost effectiveness of vacuum dressings in reducing the incidence of surgical site infection in obese women undergoing elective and semi-urgent caesarian section. The trial will be conducted at 4 hospitals in south east Queensland. 2,100 women undergoing caesarian section will either receive a vacuum or standard surgical dressing and will be followed for 1 month after surgery.
The Impact Of Introducing Medical Emergency Team On The Reduction Of Hospital Mortality And Other Adverse Events In NSW
Funder
National Health and Medical Research Council
Funding Amount
$581,827.00
Summary
High numbers of patients suffer an adverse event or die in hospitals needlessly. Summoned by a set of pre-specified criteria, a Medical Emergency Team (MET) rapidly respond to patients on general wards to prevent further deterioration. Previous studies have shown its impact on reducing cardiac arrests but limited high level evidence on reducing hospital deaths. Current study uses linked administrative databases and well-established indicators to assess the impact of introduction of a MET in NSW.
The Evaluation Of A Statewide Innovative Patient Safety Improvement System On Reducing Hospital Mortality And Other Adverse Events - A Population-based Mixed-method Study
Funder
National Health and Medical Research Council
Funding Amount
$724,555.00
Summary
Research indicates that one in ten patients admitted to hospital suffered an adverse event. Studies have shown that the adverse clinical outcomes (e.g. cardiac arrest or death) often exhibit early warning signs such as slow deterioration of vital signs hours before such an event. Clinical Excellence Commission of NSW implemented a world-first standardised patient safety system (i.e., Between the Flag) to address the issues. We aim to provide an evaluation of the effectiveness of this system.
An Investigation Of The Patient Experience Of Adverse Events.
Funder
National Health and Medical Research Council
Funding Amount
$587,543.00
Summary
Harm during health care (referred to as adverse events) can be serious. Reporting systems have been developed but patients’ experiences of adverse events have remained alarmingly absent. In order to be fully effective policy and services must be designed with these experiences in mind. This study will provide a unique and comprehensive picture of the occurrence of adverse events from the patient's perspective and use this data to enhance policy and service responses.
Pharmacotherapy For Smoking Cessation Prior To And During Pregnancy
Funder
National Health and Medical Research Council
Funding Amount
$620,950.00
Summary
This study will examine the effectiveness and safety of medications for smoking cessation prior to and during pregnancy. It will achieve this by linking routinely collected midwives data from NSW and WA to prescriptions records and other health service use. It will explore potential inequalities in the use and effectiveness of these medications in disadvantaged populations, including Aboriginal women, and it will investigate whether their use has changed in response to policy changes.
Value Of Androgen Deprivation And Bisphosphonate In Patients Treated By Radiotherapy For Localised Prostate Cancer
Funder
National Health and Medical Research Council
Funding Amount
$2,533,827.00
Summary
Following on from significant findings in the TROG 96.01 trial, the 03.04 trial, known as the RADAR trial was developed. This is a large-scale randomised controlled clinical trial currently conducted at 23 cancer treatment centres throughout Australia and New Zealand. The RADAR trial aims to recruit 1000 men with localised but inoperable prostate cancer. It was anticipated that the length of time required to enrol 1000 participants to the trial would be 5 years. However, because enrolment has ex ....Following on from significant findings in the TROG 96.01 trial, the 03.04 trial, known as the RADAR trial was developed. This is a large-scale randomised controlled clinical trial currently conducted at 23 cancer treatment centres throughout Australia and New Zealand. The RADAR trial aims to recruit 1000 men with localised but inoperable prostate cancer. It was anticipated that the length of time required to enrol 1000 participants to the trial would be 5 years. However, because enrolment has exceeded expectations and 728 patients have already been recruited, it is anticipated that the recruitment target will be reached in mid 2007. Patients are randomly assigned to receive one of four treatment options in the RADAR trial. The first option: Option A: Radiation Therapy and 6 months of Hormone Therapy (Leuprorelin acetate), is currently the standard of care. Option C is a further 12 months of hormone therapy after the current standard of care. Two of the options (B and D) are identical to options A and C except that subjects also receive 18 months of zoledronate (a 'bone' drug) in addition to hormone therapy and radiotherapy. The main goal of the RADAR trial is to determine whether 12 months of hormone therapy using Leuprorelin acetate starting immediately after standard therapy (ie 6 months of Leuprorelin acetate before and during radiotherapy) will reduce risk of return of the cancer, either within the prostate region or at remote sites in the body, and prolong life. An additional goal is to see whether 18 months of bisphosphonate therapy (bone density therapy) using zoledronate will reduce the risk of cancer returning in the bones as well as stopping dangerous bone thinning which can sometimes be caused by hormone therapy. The trial also seeks to determine whether the additional therapy given in this trial alters quality of life.Read moreRead less
Optimal Duration Of Neoadjuvant Androgen Deprivation Therapy In Localised Prostate Cancer Treated By Radiotherapy
Funder
National Health and Medical Research Council
Funding Amount
$422,335.00
Summary
The 96.01 trial aims to find out whether androgen deprivation (AD) administered prior to and during radiotherapy (i.e., neo-adjuvant AD) will improve outcomes in patients with locally advanced prostate cancer that is considered inoperable and is treated for cure by radiotherapy. The trial also aims to find out whether six months AD produces outcomes superior to those achieved by three months AD. The trial has been running since 1996 and involves 802 men who attend 19 cancer treatment centres acr ....The 96.01 trial aims to find out whether androgen deprivation (AD) administered prior to and during radiotherapy (i.e., neo-adjuvant AD) will improve outcomes in patients with locally advanced prostate cancer that is considered inoperable and is treated for cure by radiotherapy. The trial also aims to find out whether six months AD produces outcomes superior to those achieved by three months AD. The trial has been running since 1996 and involves 802 men who attend 19 cancer treatment centres across Australia and New Zealand. It would not have been possible without the continuous funding support of the NHMRC. So far this trial has shown that AD does prevent prostate cancer from returning after radiotherapy. This is very important because the need for treatment of recurrent cancer (usually AD for the rest of the patient's life) is halved by 6 months AD compared to standard treatment (radiotherapy alone). However, it is now necessary to observe the patients in this trial for another 5 years to find out whether AD also prolongs life, and whether 6 months AD is more effective than 3 months. Further patient follow up is also necessary to identify whether some men respond better to treatment than others. This is very important because it will enable treatment to be tailored to individual patients, in particular those who require more treatment than is given in this trial. This funding application is therefore to enable patient follow up on this large scale trial for another 5 years.Read moreRead less